Psychedelic Research in
Armenia
Armenia appears to have a tightly controlled psychedelics environment, with no linked trials, stakeholders or events in Blossom's database and no obvious domestic clinical programme in the public sources reviewed. The clearest visible research capacity is general psychiatry and clinical science at major Yerevan institutions, including Yerevan State Medical University and Erebouni Medical Centre, but not a documented local psychedelics research pipeline.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Armenia.
- 1
The public evidence reviewed does not show an active Armenian psychedelics research ecosystem, which is consistent with Blossom's zero counts for linked trials, stakeholders and events.
- 2
Armenia does have relevant psychiatric and academic infrastructure in Yerevan, including a psychiatry department at YSMU that reports international research activity and hospital-based centres involved in clinical and scientific work.
- 3
The legal baseline is restrictive: UNODC's copy of Armenian narcotics law describes controlled lists and criminal penalties for illicit turnover, supporting a cautious interpretation of access for psychedelics.
- 4
Recent policy activity appears to emphasise mental health-system strengthening and international drug-control cooperation rather than liberalisation of psychedelic medicines.
- 5
Any practical ketamine access should still be treated narrowly as standard medical/anesthetic use, not as an endorsed psychedelic-therapy pathway.
Research Snapshot
Blossom currently keeps Armenia as a country index, but no psychedelic clinical trials, stakeholders or events are linked to this country in the database yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
In Armenia, ketamine is an established medical anesthetic and is available for licensed medical use; however, its use for psychiatric indications is off-label and not publicly reimbursed. Most classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) are scheduled as controlled psychotropic/narcotic substances under Armenian law with no authorized medical use outside approved clinical research.
Regulatory Status
Armenia's legal framework, as reflected in UNODC's legislation database, places narcotic drugs and psychotropic substances under government control and distinguishes prohibited substances from those subject to restricted or conditional traffic. On that basis, and consistent with Blossom's access-guide snapshot, ketamine can be understood as available for established medical use, but psychiatric use would be off-label and not clearly publicly reimbursed; by contrast, classic psychedelics such as psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline and 2C-X appear to remain controlled with no evident authorised medical access pathway beyond approved research, if any.
Country Details
- Region
- Asia
- Last updated
- 4 May 2026
Country Report
Mixed (Medical available for ketamine; others controlled)Medical Access and Reimbursement
In Armenia, ketamine is an established medical anesthetic and is available for licensed medical use; however, its use for psychiatric indications is off-label and not publicly reimbursed. Most classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca, mescaline, 2C-X) are...
Open access guide →